Based on a resolution passed by the Executive Board today, JENOPTIK AG (FSE: JEN / ISIN: DE000A2NB601) announces key figures of the guidance for fiscal year 2023. Due to the good order intake, the high order backlog, and ongoing good developments in the core photonics businesses, especially in the semiconductor equipment sector, Jenoptik is anticip [ … ]

Based on a resolution passed by the Executive Board today, JENOPTIK AG (FSE: JEN / ISIN: DE000A2NB601) announces key figures of the guidance for fiscal year 2023. Due to the good order intake, the high order backlog, and ongoing good developments in the core photonics businesses, especially in the semiconductor equipment sector, Jenoptik is anticip [ … ]

JENOPTIK AG signs agreement to sell VINCORION JENOPTIK AG (FSE: JEN / ISIN: DE000A2NB601) has signed an agreement to sell the VINCORION division. It will be acquired by a fund managed by STAR Capital Partnership LLP ("STAR"). STAR is a leading private equity firm investing in medium-sized companies across Europe. VINCORION develops, produces, and [ … ]

Jenoptik strengthens global photonics business with the acquisition of Berliner Glas Medical and SwissOptic JENOPTIK AG (FSE: JEN / ISIN: DE000A2NB601) is set to acquire from Berliner Glas GmbH, a wholly-owned subsidiary of ASML Holding N.V., a 100 percent stake in BG Medical Applications GmbH ("Berliner Glas Medical"), a supplier of high-precisi [ … ]

The Jenoptik Group achieved record figures in order intake, revenue and EBITDA in the 2nd quarter 2021. From April to June order intake almost doubled compared with the prior-year period, revenue grew by almost 30 percent and EBITDA by approx. 120 percent. In particular the very good development in the Light & Optics division, especially in the [ … ]

JENOPTIK AG's Executive Board today gained fundamental information in the process of preparing the consolidated financial statements for fiscal year 2020 that the Group's adjusted EBITDA margin will probably reach around 17.5 percent, and thus will be significantly above the expected range of between 15.0 and 15.5 percent (including TRIOPTICS / bef [ … ]

According to preliminary estimates the order intake of the Jenoptik Group stabilized at previous year's level in the third quarter, following a weak second quarter. Revenue in the third quarter is below the prior year's figure, but has increased compared to the second quarter of 2020. Due to the continuing weak overall economic development and a si [ … ]